We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+20.66%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$352M
Cap. Flow
-$18.8M
Cap. Flow %
-0.71%
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.4M
3
ABT icon
Abbott
ABT
+$12.5M
4
MIST icon
Milestone Pharmaceuticals
MIST
+$12.4M
5
CI icon
Cigna
CI
+$12M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$146M
2
UNH icon
UnitedHealth
UNH
+$23.1M
3
ISRG icon
Intuitive Surgical
ISRG
+$9.43M
4
HUM icon
Humana
HUM
+$9.27M
5
ZTS icon
Zoetis
ZTS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 94.16%
2 Real Estate 3.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
201
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$354K 0.01%
+5,677
New +$270K
GH icon
202
Guardant Health
GH
$20.2B
$339K 0.01%
+4,333
New +$312K
MRUS
203
DELISTED
Merus
MRUS
$299K 0.01%
21,215
-206
-1% -$3.31K
DNTH icon
204
Dianthus Therapeutics
DNTH
$6.16B
$254K 0.01%
1,047
– –
ORKA
205
Oruka Therapeutics
ORKA
$5.9B
$206K 0.01%
3,006
– –
CBAY
206
DELISTED
Cymabay Therapeutics
CBAY
$173K 0.01%
88,102
– –
WHWK
207
Whitehawk Therapeutics
WHWK
$190M
$161K 0.01%
17,170
– –
TTPH
208
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$121K ﹤0.01%
42,965
-1
-0% -$3
MNK
209
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$115K ﹤0.01%
32,980
– –
NVAX icon
210
Novavax
NVAX
$1.22B
$114K ﹤0.01%
28,550
– –
ADAP
211
DELISTED
Adaptimmune Therapeutics
ADAP
$92K ﹤0.01%
77,061
– –
BLCM
212
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$77K ﹤0.01%
6,000
– –
QHC
213
DELISTED
Quorum Health Corporation
QHC
$23K ﹤0.01%
23,725
– –
CLDX icon
214
Celldex Therapeutics
CLDX
$3.02B
$16K ﹤0.01%
7,053
– –
CAH icon
215
Cardinal Health
CAH
$53.2B
– –
-58,241
Closed -$2.75M
WMGI
216
DELISTED
Wright Medical Group Inc
WMGI
– –
-124,006
Closed -$2.56M
DPLO
217
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-214,845
Closed -$1.05M
CELG
218
DELISTED
Celgene Corp
CELG
– –
-1,473,710
Closed -$146M
5 6 7 8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Tekla Capital Management held 218 positions worth $2.64B, up 15% from $2.29B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2019 filing shows 26 new, 62 increased, 55 reduced and 4 closed positions. Its largest new stake was Centene: 149,526 shares worth $9.4M. The largest sale was Celgene Corp, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2019 buy was Centene: 149,526 shares worth $9.4M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q4 2019, an estimated $14M increase.
  • Tekla Capital Management's biggest Q4 2019 reduction was UnitedHealth, cutting an estimated $23.1M.
  • Tekla Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $146M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.64B portfolio in Q4 2019.
  • Tekla Capital Management opened 26 new positions and closed 4 in Q4 2019.
  • Tekla Capital Management's portfolio value rose 15% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.